Their results indicated that liproxstatin-1, a ferroptosis inhibitor, could alleviate radiation-induced lung fibrosis via down-regulation of TGF-β1 and activation of the Nrf2 signaling pathway, providing a novel therapeutic target for patients with radiation-induced lung fibrosis. This evidence concerns the gene TGFB1 and pulmonary fibrosis.